Health experts call on governments to address rising rate of obesity

Nearly $28-billion: Obesity Canada estimates untreated obesity costs Canada nearly $28 billion annually, with almost 70% of adults classed as overweight or obese in 2022-24 and half of adults having abdominal obesity. Only Alberta has formally recognized obesity as a chronic disease (March 4, 2025), while the federal government and most provinces have not, limiting coordinated funding and coverage for treatments such as GLP-1 drugs (Ozempic/Wegovy). The expected entry of at least three semaglutide generics could lower prices to ~35% of brand cost, which may alter provincial willingness to fund pharmacotherapy. Continued policy inaction risks rising health-system expenditures and unequal access, particularly for vulnerable populations.

Analysis

Policy inertia among provincial payers creates a predictable interim market: branded GLP-1/GLP receptor agonist makers retain a high-margin, self-pay window even as structural forces push toward broader public coverage. That window is finite — we model a 12–36 month commercial tail during which unit volumes can expand materially while average realized prices begin to face downward pressure from generic entries and payer negotiations. Investors should think in terms of duration: near-term revenue growth (quarters) versus multi-year margin compression as generics scale.

The most durable winners are firms controlling sterile-injectable capacity, distribution logistics, and specialty pharmacy channels; they capture incremental margin irrespective of who ultimately pays. Conversely, exposure to self-pay dependent clinic models is a two-way trade: provincial coverage can either redirect referrals into regulated pathways (benefit) or displace private revenue if formularies favor generics and centralized dispensing (risk). Expect negotiating dynamics where payers demand outcome-based contracting and volume discounts, pressuring list-price-driven business models.

Key catalysts and risks are policy and product-timelines: provincial budget cycles and public-health recognition decisions (near-term) and the arrival of multiple generic suppliers (12–36 months) will dominate valuation swings. Tail risks include accelerated price controls or safety/regulatory issues that could truncate demand rapidly. Active positioning should therefore be asymmetric — capture upside from adoption acceleration while explicitly hedging horizon-specific downside from price erosion.

Key Decisions for Investors

• Long Eli Lilly (LLY) via a 9–12 month call spread (buy 1x near-term call, sell a higher strike) to capture continued branded demand while capping premium exposure; reward if adoption accelerates, risk limited to net premium paid.
• Long Catalent (CTLT) or Lonza-equivalent exposure (CTLT preferred) for 6–18 months to play sterile-injectable capacity tightness; use outright stock or 12-month calls. Upside: margin expansion from contract fills; downside: biotech capex cadence could re-rate shares.
• Long Canadian digital/EMR care platforms (e.g., WELL.TO) 12–24 months to capture provincial rollouts that require centralized care pathways and data integration; size as a satellite position — payoff if provinces formalize coordinated programs, downside if budgets constrain IT spend.
• Hedge branded drug exposure with long-dated protection: buy 18–24 month puts on a core branded exposure (LLY or NVO) or allocate to protective collars to insure against generic-driven price collapse within the 12–36 month window; cost justified by asymmetric downside risk.